Tumor deposit is a poor prognostic indicator in patients who underwent simultaneous resection for synchronous colorectal liver metastases

Figures & data

Table 1 The correlation between the clinicopathological factors and the status of tumor deposits in patients who underwent simultaneous resection for synchronous colorectal liver metastases

Variables	Patients		Tumor deposits		P-value
	No	%	Positive	Negative
	146	100	61	85
Age (years)					0.596
≤60	96	65.8	42	54
>60	50	34.2	19	31
Sex					0.913
Male	83	56.8	35	48
Female	63	43.2	26	37
Tumor location					0.424
Colon	101	69.2	40	61
Rectum	45	30.8	21	24
Histological type					0.304
Adenocarcinoma	124	84.9	54	70
Mucinous adenocarcinoma	22	15.1	7	15
Tumor differentiation					0.227
Well, moderate	78	53.4	29	49
Poor and others	68	46.6	32	36
Primary tumor (T) stage					1.000
T1, T2	6	4.1	2	4
T3, T4	140	95.9	59	81
Primary nodal (N) stage					0.002
Absent	57	39.0	15	42
Present	89	61.0	46	43
Vascular invasion					0.113
Absent	121	82.9	47	74
Present	25	17.1	14	11
Nerve invasion					0.041
Absent	129	88.4	50	79
Present	17	11.6	11	6
No of metastases					0.130
≤3	129	88.4	51	78
≥4	17	11.6	10	7
Largest metastasis					0.673
<5 cm	105	71.9	45	60
≥5 cm	41	28.1	16	25
Carcinoembryonic antigen					0.952
≤5 ng/mL	46	31.5	19	27
>5 ng/mL	98	68.5	41	57

Figure 1 Analyses of overall survival and disease-free survival according to the status of tumor deposits in synchronous colorectal liver metastases (SCRLM) patients.

Notes: (A) Kaplan–Meier analyses of overall survival according to status of tumor deposits in SCRLM patients (n=146; P=0.039). (B) Kaplan–Meier analyses of disease-free survival according to status of tumor deposits in SCRLM patients (n=146; P=0.001).

Table 2 Univariate and multivariate analyses of associations between clinicopathological factors and overall survival in patients who underwent simultaneous resection for synchronous colorectal liver metastases

Prognostic factor	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
Age (>60:≤60)	0.623	0.320–1.214	0.165
Sex (female:male)	1.620	0.890–2.949	0.115
Primary tumor site (rectum:colon)	1.314	0.706–2.443	0.389
Histological type (mucinous adenocarcinoma: adenocarcinoma)	0.795	0.313–2.023	0.631
Tumor differentiation (well, moderate: poor and others)	1.564	0.850–2.880	0.151
Primary tumor (T) stage (T3, T4:T1, T2)	2.585	0.355–18.803	0.348
Primary nodal (N) stage (N1, N2:N0)	3.304	1.530–7.132	0.002	4.200	1.912–9.224	<0.001
Vascular invasion (positive:negative)	2.616	1.308–5.230	0.007	3.561	1.688–7.514	0.001
Nerve invasion (positive:negative)	2.569	1.068–6.177	0.035	1.622	0.651–4.042	0.299
No of liver metastases (≥4: ≤3)	1.485	0.984–5.643	0.022	3.408	1.478–7.859	0.004
Size of liver metastases (≥5 cm:<5 cm)	2.589	1.145–5.854	0.237
Extrahepatic metastases resection (yes:no)	2.198	0.677–7.134	0.190
CEA (.5 ng/mL:>5 ng/mL)	1.824	0.896–3.715	0.098	1.647	0.805–3.368	0.172
Chemotherapy (postoperative:perioperative)	1.077	0.561–2.069	0.824
Tumor deposits (positive:negative)	1.859	1.019–3.389	0.043	1.541	0.820–2.895	0.179

Abbreviations: HR, hazard ratio; CI, confidence interval.

Table 3 Univariate and multivariate analyses of associations between clinicopathological factors and disease-free survival in patients who underwent simultaneous resection for synchronous colorectal liver metastases

Prognostic factor	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
Age (>60:≤60)	0.671	0.408–1.104	0.116
Sex (female:male)	1.529	0.971–2.409	0.067	1.541	0.976–2.432	0.063
Primary tumor site (rectum:colon)	1.313	0.819–2.104	0.258
Histological type (mucinous adenocarcinoma: adenocarcinoma)	0.620	0.298–1.292	0.202
Tumor differentiation (well, moderate: poor and others)	1.423	0.898–2.255	0.133
Primary tumor (T) stage (T3, T4:T1, T2)	1.539	0.484–4.893	0.465
Primary nodal (N) stage (N1, N2:N0)	1.611	0.991–2.620	0.054	1.404	0.827–2.384	0.209
Vascular invasion (positive:negative)	1.482	0.828–2.652	0.185
Nerve invasion (positive:negative)	1.453	0.722–2.926	0.295
No of LMs (≥4:≤3)	2.333	1.251–4.351	0.008	2.380	1.268–4.469	0.007
Size of LM (≥5 cm:<5 cm)	1.420	0.872–2.312	0.159
Extrahepatic metastases resection (yes:no)	2.670	1.068–6.675	0.036	1.716	0.661–4.454	0.267
CEA (>5 ng/mL:>5 ng/mL)	1.429	0.868–2.352	0.160
Chemotherapy (postoperative:perioperative)	1.108	0.663–1.852	0.696
Tumor deposits (positive:negative)	2.149	1.360–3.396	0.001	2.080	1.316–3.290	0.002

Abbreviations: HR, hazard ratio; CI, confidence interval.

Figure 2 Analyses of overall survival and disease-free survival according to the status of tumor deposits in synchronous colorectal liver metastases (SCRLM) patients with negative lymph node.

Notes: (A) Kaplan–Meier analyses of overall survival according to status of tumor deposits in SCRLM patients with negative lymph node (n=57; P=0.002). (B) Kaplan–Meier analyses of disease-free survival according to status of tumor deposits in SCRLM patients with negative lymph node (n=57; P=0.031).

Figure 3 Analyses of overall survival and disease-free survival according to the status of tumor deposits in synchronous colorectal liver metastases (SCRLM) patients with positive lymph node.

Notes: (A) Kaplan–Meier analyses of overall survival according to status of tumor deposits in SCRLM patients with positive lymph node (n=89; P=0.965). (B) Kaplan–Meier analyses of disease-free survival according to status of tumor deposits in SCRLM patients with positive lymph node (n=89; P=0.034).